Incyte Corporation
$ 120.56
1.84%
07 Aug - close price
- Market Cap 24,437,240,000 USD
- Current Price $ 120.56
- High / Low $ 120.88 / 117.38
- Stock P/E 15.36
- Book Value 31.57
- EPS 7.85
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.17 %
- ROE 0.31 %
- 52 Week High 132.60
- 52 Week Low 78.20
About
Incyte Corp is an American pharmaceutical company based in Alapocas, Delaware.
Analyst Target Price
$124.96
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-07-28 | 2026-04-28 | 2026-02-10 | 2025-10-28 | 2025-07-29 | 2025-04-29 | 2025-02-10 | 2024-10-29 | 2024-07-30 | 2024-04-30 | 2024-02-13 | 2023-10-31 |
| Reported EPS | 2.8 | 1.81 | 1.8 | 2.26 | 1.57 | 1.16 | 1.43 | 1.07 | -1.82 | 0.64 | 1.06 | 1.1 |
| Estimated EPS | 1.76 | 1.34 | 1.92 | 1.64 | 1.47 | 1.03 | 1.55 | 1.09 | 1.11 | 0.83 | 1.15 | 1.07 |
| Surprise | 1.04 | 0.47 | -0.12 | 0.62 | 0.1 | 0.13 | -0.12 | -0.02 | -2.93 | -0.19 | -0.09 | 0.03 |
| Surprise Percentage | 59.0909% | 35.0746% | -6.25% | 37.8049% | 6.8027% | 12.6214% | -7.7419% | -1.8349% | -263.964% | -22.8916% | -7.8261% | 2.8037% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: INCY
2026-08-07 06:38:19
Oppenheimer has increased its price target for Incyte Corp. (NASDAQ:INCY) to $107 from $90, maintaining an Outperform rating after Incyte acquired Vega Therapeutics. The acquisition adds VGA039, a Phase 3-ready Protein S modulator for von Willebrand disease, which Oppenheimer believes could be a significant long-term growth asset exceeding $1 billion and help diversify Incyte's revenue as its key drug, Jakafi, faces loss of exclusivity. This move is seen as strengthening Incyte's hematology franchise and boosting its financial outlook, despite concerns from other analysts about Jakafi's future sales.
2026-08-06 20:38:02
Incyte Corp. (INCY) shares decreased by 1.19% to $118.38 on Thursday, despite a broader market decline where the S&P 500 Index fell 0.18% and the Dow Jones Industrial Average dropped 0.85%. This marks the second consecutive day of losses for Incyte, yet the stock still managed to outperform its competitors relative to the wider market's performance.
2026-08-06 19:10:51
Halozyme Therapeutics Inc. is reporting second-quarter earnings, with investors keenly watching its partnership momentum and progress toward a $1 billion ENHANZE royalty revenue target. The company has shown strong growth and secured multiple licensing deals, contributing to its stock trading near 52-week highs. Investors will focus on new partnership additions and the sustainability of its growth trajectory.
2026-08-06 13:40:11
CRISPR Therapeutics AG (NASDAQ:CRSP) reported strong second-quarter revenues of US$10 million, significantly beating estimates by 37%, and a smaller-than-expected loss of US$0.94 per share. Following these results, analysts have raised their revenue forecasts for 2026 to US$54.4 million and slightly reduced loss per share estimates, indicating a bullish outlook. Despite these upgrades, the consensus price target remains unchanged at US$87.17, although individual analyst targets show a wide divergence.
2026-08-05 03:40:48
Syndax Pharmaceuticals reported strong commercial growth in Q2 2026, with combined revenue from Revuforj and Niktimvo reaching $115 million. Revuforj sales increased 91% year-over-year, driven by increased treatment duration, while Niktimvo grew 67% year-over-year, expanding its market share in chronic GVHD. The company also highlighted significant pipeline progress with new assets and upcoming data readouts that could unlock multi-billion dollar opportunities, affirming its financial stability and path to profitability.
2026-08-04 20:08:25
Patrick A. Mayes, EVP & Chief Scientific Officer of Incyte (INCY), exercised stock options for 45,767 shares and subsequently sold 47,954 shares of common stock on July 31 and August 3, 2026, through a Rule 10b5-1 trading plan. The sales amounted to approximately $5.73 million, with exercise costs around $3.59 million. Mayes's holdings also include 59,537 unvested restricted stock units.
